Letermovir tablets (Letermovir) medical insurance inclusion status, reimbursement conditions and cost reference instructions

Letermovir tablets (Letermovir) is an antiviral drug mainly used to prevent cytomegalovirus (CMV) infection in patients with hematopoietic stem cell transplantation (HSCT). The drug is already on the market in China, and both tablet and injection forms have been included in the national medical insurance catalog, allowing patients to enjoy partial reimbursement policies during treatment, thereby reducing the financial burden. After being included in medical insurance, for patients who meet clinical indications, a certain percentage of drug costs can be paid through medical insurance, but the specific reimbursement amount and self-payment ratio still need to be determined according to local policies and hospital pharmacy regulations.

In the domestic market, the price of letermovir tablets is usually around 10,000 yuan per box, while the injection price is about 500 to 600 yuan per box. The price difference is mainly due to the differences in dosage form, production cost and administration method. Medical insurance reimbursement conditions generally require that patients be at high risk for CMV after hematopoietic stem cell transplantation, and that they be used under the guidance of a doctor's prescription. The reimbursement ratio and scope may vary due to differences in regional medical insurance policies. Therefore, patients should consult the hospital pharmacy and medical insurance department before use to ensure that they meet the conditions to obtain reimbursement support.

Letermovir is also sold in overseas markets, including original drugs and generic drugs. The price of each box of generic tablets produced by Lucius in Laos is about 2,000 yuan, which is more affordable than the original drug. This provides certain options for patients who need to purchase drugs across the border or who are temporarily unable to obtain drugs domestically. However, when choosing overseas generic drugs, attention should be paid to the formality of drug sources, quality control, and transportation and storage conditions to ensure drug safety and efficacy.

In general, the domestic launch of letermovir and its inclusion in medical insurance have enabled high-risk HSCT patients to receive standardized and reimbursable CMV preventive treatment. Patients should strictly follow the doctor's prescription when using it, choose the appropriate dosage form based on their own condition and economic situation, and pay attention to changes in medical insurance policies and pharmacy prices in a timely manner. In the future, as the population of drug users expands and policies are improved, the reimbursement ratio is expected to be further optimized, and the economic accessibility and clinical convenience of long-term medication will also be improved.

Reference materials:https://www.mayoclinic.org/drugs-supplements/letermovir-oral-route/description/drg-20406647